Dr Reddy's to launch Covid drugs remdesivir and favipiravir in August

Trying to boost acquired Wockhardt portfolio which saw sharp decline in sales during pandemic

Hyderabad-based Dr Reddy's Laboratories (DRL) is gearing up for two major launches next month - injectable drug remdesivir for hospitalised Covid-19 patients, and oral drug favipiravir that is given to mild to moderate patients. 

While the company admitted that its India revenues were hit due to lower prescription generation and a sluggish growth in the acquired Wockhardt portfolio, it is bullish on its Covid-19 portfolio nonetheless. 

Apart from favipiravir and remdesivir, its key Covid-19 products, DRL has already launched nutraceutical products and hand sanitisers during the pandemic. Products like azithromycin (common antibiotic used in Covid) have also seen traction, DRL